Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma 2Breast Neoplasms 2Vomiting 1Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solitary Fibrous Tumors 1Sarcoma 1Postoperative Nausea and Vomiting 1Neoplasm Metastasis 1Multiple Myeloma 1Liposarcoma 1Leukemia, Hairy Cell 1Histiocytoma, Malignant Fibrous 1Dermatofibrosarcoma 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Carcinoma In Situ 1Adenocarcinoma, Mucinous 1

Interventions

Paclitaxel 2Nivolumab 2Immunoglobulin G 2Disulfides 2Bevacizumab 2atezolizumab 1Taxes 1Specimen Handling 1Oxaliplatin 1Magnetic Resonance Spectroscopy 1Leucovorin 1Ipilimumab 1Gemcitabine 1Fluorouracil 1Famotidine 1Docetaxel 1Diphenhydramine 1Dexamethasone 1Carboplatin 1Calcium Dobesilate 1CTLA-4 Antigen 1Axitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenocarcinoma, Mucinous × Famotidine × 1 year × Clear all
NCT06207305 2026-01-13

A Phase I/II Study of Intraperitoneal Paclitaxel in Patients With Metastatic Appendiceal Adenocarcinoma

M.D. Anderson Cancer Center

Phase 1/2 Recruiting
39 enrolled

Adenocarcinoma, Mucinous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡